Century Therapeutics (NASDAQ:IPSC) SVP Sells $17,959.65 in Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) SVP Douglas Carr sold 7,043 shares of Century Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $2.55, for a total transaction of $17,959.65. Following the completion of the transaction, the senior vice president directly owned 507,261 shares in the company, valued at approximately $1,293,515.55. The trade was a 1.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Douglas Carr also recently made the following trade(s):

• On Tuesday, February 3rd, Douglas Carr sold 323 shares of Century Therapeutics stock. The shares were sold at an average price of $1.82, for a total transaction of $587.86.

Century Therapeutics Stock Up 0.4%

Shares of IPSC stock opened at $2.30 on Thursday. The firm has a fifty day moving average of $2.16 and a 200-day moving average of $1.15. Century Therapeutics, Inc. has a 12-month low of $0.34 and a 12-month high of $3.04. The company has a market capitalization of $201.03 million, a price-to-earnings ratio of -16.43 and a beta of 1.70.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. On average, equities analysts expect that Century Therapeutics, Inc. will post -1.61 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on IPSC shares. Zacks Research lowered Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 12th. Leerink Partners set a $2.00 price objective on Century Therapeutics and gave the stock a “market perform” rating in a report on Friday, March 13th. TD Cowen began coverage on Century Therapeutics in a research report on Wednesday, February 25th. They issued a “buy” rating on the stock. Piper Sandler boosted their target price on Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Finally, Wall Street Zen raised Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Century Therapeutics has an average rating of “Moderate Buy” and an average target price of $3.80.

Hedge Funds Weigh In On Century Therapeutics

Institutional investors have recently bought and sold shares of the business. Prudential Financial Inc. acquired a new position in Century Therapeutics during the second quarter worth approximately $25,000. Qube Research & Technologies Ltd acquired a new stake in shares of Century Therapeutics in the second quarter valued at approximately $38,000. Raymond James Financial Inc. bought a new position in shares of Century Therapeutics during the 2nd quarter worth approximately $51,000. AQR Capital Management LLC boosted its stake in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after acquiring an additional 86,875 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after acquiring an additional 34,466 shares during the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.